For women dealing with estrogen receptor-positive breast cancer, finding a treatment that works quickly is vital. A recent Phase III trial looked at what happens when patients take an aromatase inhibitor—a common hormone therapy—alongside the drug celecoxib for 16 weeks.
The study involved 269 postmenopausal women with tumors at least 2 centimeters in size. The results showed that adding celecoxib significantly improved the clinical response rate, jumping from 55.6% in the placebo group to 72.9% in the group receiving both medications. This suggests a stronger initial reaction to the treatment.
While the early clinical response was better with celecoxib, other measures told a different story. Ultrasound-determined responses and long-term outcomes like progression-free survival or overall survival did not show significant differences between the two groups. The study also confirmed that using celecoxib for 16 weeks was safe and did not cause extra heart issues.
Common questions
Does adding celecoxib improve the treatment's effectiveness?
The study found that adding 400mg of celecoxib twice a day to hormone therapy significantly improved the clinical response rate at 16 weeks, reaching 72.9% compared to 55.6% with a placebo. However, this did not result in different outcomes for ultrasound-determined response or long-term survival.
Is it safe to take celecoxib with hormone therapy?
The trial reported that using 400mg of celecoxib twice a day for 16 weeks was safe. The researchers specifically noted that no extra heart problems were observed in the group taking the combination of aromatase inhibitors and celecoxib.
Does this treatment help women live longer?
While the initial clinical response was better with the addition of celecoxib, the study did not find a significant difference in progression-free survival or overall survival between the two groups. You should talk to your doctor about how these results apply to your specific situation.
